BRPI0821069A2 - Derivados de oxadiazol ativos em 1-fosfa de esfingosina (s1p) - Google Patents

Derivados de oxadiazol ativos em 1-fosfa de esfingosina (s1p)

Info

Publication number
BRPI0821069A2
BRPI0821069A2 BRPI0821069-1A BRPI0821069A BRPI0821069A2 BR PI0821069 A2 BRPI0821069 A2 BR PI0821069A2 BR PI0821069 A BRPI0821069 A BR PI0821069A BR PI0821069 A2 BRPI0821069 A2 BR PI0821069A2
Authority
BR
Brazil
Prior art keywords
sphingosine
phosphate
oxadiazole derivatives
derivatives active
active
Prior art date
Application number
BRPI0821069-1A
Other languages
English (en)
Inventor
Jag Paul Heer
Thomas Daniel Heightman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI0821069A2 publication Critical patent/BRPI0821069A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BRPI0821069-1A 2007-12-21 2008-12-19 Derivados de oxadiazol ativos em 1-fosfa de esfingosina (s1p) BRPI0821069A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0725101.0A GB0725101D0 (en) 2007-12-21 2007-12-21 Compounds
PCT/EP2008/067963 WO2009080724A1 (en) 2007-12-21 2008-12-19 Oxadiazole derivatives active on sphingosine-1-phosphate (s1p)

Publications (1)

Publication Number Publication Date
BRPI0821069A2 true BRPI0821069A2 (pt) 2015-06-16

Family

ID=39048651

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821069-1A BRPI0821069A2 (pt) 2007-12-21 2008-12-19 Derivados de oxadiazol ativos em 1-fosfa de esfingosina (s1p)

Country Status (23)

Country Link
US (2) US8278324B2 (pt)
EP (2) EP2225233B1 (pt)
JP (1) JP2011506568A (pt)
KR (1) KR20100108568A (pt)
CN (1) CN101945864A (pt)
AU (1) AU2008339987B2 (pt)
BR (1) BRPI0821069A2 (pt)
CA (1) CA2710067A1 (pt)
CO (1) CO6290688A2 (pt)
CR (1) CR11578A (pt)
DK (1) DK2225233T3 (pt)
DO (1) DOP2010000187A (pt)
EA (1) EA018637B1 (pt)
ES (1) ES2431795T3 (pt)
GB (1) GB0725101D0 (pt)
HR (1) HRP20131053T1 (pt)
IL (1) IL206278A0 (pt)
MA (1) MA31922B1 (pt)
NZ (1) NZ585994A (pt)
PL (1) PL2225233T3 (pt)
PT (1) PT2225233E (pt)
UA (1) UA102539C2 (pt)
WO (1) WO2009080724A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
GB0725101D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0807910D0 (en) 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
GB0910674D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
EP2481740B1 (en) * 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
SI2958913T1 (sl) 2013-02-20 2018-12-31 Lg Chem, Ltd. Sfingozin-1-fosfat receptor agonisti, postopki za njegovo pripravo in farmacevtski sestavki, ki ga vsebujejo kot aktivno sredstvo
CA3066423A1 (en) * 2017-06-14 2018-12-20 Trevena, Inc. Compounds for modulating s1p1 activity and methods of using the same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP2005533058A (ja) 2002-06-17 2005-11-04 メルク エンド カムパニー インコーポレーテッド Edg受容体アゴニストとしての1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)アゼチジン−3−カルボキシラートおよび1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)ピロリジン−3−カルボキシラート
WO2004113330A1 (en) 2003-05-19 2004-12-29 Irm Llc Immunosuppressant compounds and compositions
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
AU2004251146A1 (en) * 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
CN1787817B (zh) * 2003-05-19 2011-09-07 Irm责任有限公司 免疫抑制剂化合物及组合物
AU2004299456B2 (en) * 2003-12-17 2010-10-07 Merck Sharp & Dohme Corp. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
JP5315611B2 (ja) * 2004-06-23 2013-10-16 小野薬品工業株式会社 S1p受容体結合能を有する化合物およびその用途
JP2008517915A (ja) * 2004-10-22 2008-05-29 メルク エンド カムパニー インコーポレーテッド S1p受容体アゴニストとしての2−(アリール)アザシクリルメチルカルボキシレート、スルホネート、ホスホネート、ホスフィネート及びヘテロ環
JP4318087B2 (ja) 2004-12-13 2009-08-19 小野薬品工業株式会社 アミノカルボン酸誘導体およびその医薬用途
BRPI0609668A2 (pt) * 2005-03-23 2011-10-18 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
CN101203512A (zh) * 2005-04-22 2008-06-18 第一三共株式会社 杂环化合物
JP2008545767A (ja) * 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 多環式オキサジアゾールまたはイソキサゾールおよびsip受容体リガンドとしてのそれらの使用
JP2009506046A (ja) * 2005-08-23 2009-02-12 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制剤化合物および組成物
MX2008012738A (es) * 2006-04-03 2009-02-06 Astellas Pharma Inc Heterocompuesto.
WO2008064337A2 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
GB0725101D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
GB0725104D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
US20100152235A1 (en) 2010-06-17
AU2008339987A1 (en) 2009-07-02
JP2011506568A (ja) 2011-03-03
IL206278A0 (en) 2010-12-30
US8278324B2 (en) 2012-10-02
EP2746254A3 (en) 2014-10-15
KR20100108568A (ko) 2010-10-07
EP2225233A1 (en) 2010-09-08
GB0725101D0 (en) 2008-01-30
ES2431795T3 (es) 2013-11-28
CA2710067A1 (en) 2009-07-02
PL2225233T3 (pl) 2014-01-31
US20100273827A1 (en) 2010-10-28
NZ585994A (en) 2012-02-24
CR11578A (es) 2010-09-23
AU2008339987B2 (en) 2013-03-21
DK2225233T3 (da) 2013-10-14
PT2225233E (pt) 2013-11-22
MA31922B1 (fr) 2010-12-01
EP2225233B1 (en) 2013-09-04
EA018637B1 (ru) 2013-09-30
DOP2010000187A (es) 2010-08-15
CN101945864A (zh) 2011-01-12
HRP20131053T1 (hr) 2013-12-06
WO2009080724A1 (en) 2009-07-02
EP2746254A2 (en) 2014-06-25
CO6290688A2 (es) 2011-06-20
EA201070781A1 (ru) 2010-12-30
UA102539C2 (ru) 2013-07-25

Similar Documents

Publication Publication Date Title
BRPI0820131A2 (pt) Derivados de oxadiazol ativos em esfingosina-1-fosfato (s1p)
CY2020036I2 (el) Δοσολογικο σχημα για εναν αγωνιστη του υποδοχεα s1p
IL200870A0 (en) Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
LTC2379069I2 (lt) S1p receptoriaus agonisto dozavimas
BRPI0818457A2 (pt) Derivados de oxadiazol
BRPI1009274A2 (pt) arquitetura de memória virtual sem uniformidade para máquinas virtuais
BRPI0919548A2 (pt) pacote para inserto
EP2364089A4 (en) Heterocyclic sphingosine-1-phosphate analogues
BRPI1013422A2 (pt) derivados de oxadiazol
IL206278A0 (en) Oxadiazole derivatives active on sphingosine-1-phosphate (s1p)
BRPI0918935A2 (pt) compostos amida úteis em terapia
DE502008002369D1 (de) Kühlmittelzuführung
BR112013013648A2 (pt) derivados de fenil oxadiazol como moduladores de receptor de esfingosina-1-fosfato(s1p)
IL224071B (en) 5-(biphenyl-r-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (s1p) receptors
EP1981154A4 (en) DYNAMOELECTRIC MACHINE
DE602007003680D1 (de) Anästhesiegerätanordnung
BRPI0815299A2 (pt) estabilizantes fosfito para composto ionoméricos de poliester
EP2045896A4 (en) DYNAMOELECTRIC MACHINE
EP1997881A4 (en) TUBERCULOSIS VACCINE
ES1069167Y (es) Maquina para tatuar
FI20075394L (fi) Polttoaineen syöttöjärjestelmän polttoainevarasto
GB0722340D0 (en) Sphingosine-1-phosphate (S1P) receptor compounds
ZA200906256B (en) Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists
ES1068918Y (es) Ficha armable perfeccionada para juegos
HK1142071A (en) Oxadiazole derivatives active on sphingosine-1-phosphate (s1p)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.